Journal Watch · Frontiers in Immunology · 2026
Is blood eosinophilia a treatable trait in chronic obstructive airway diseases?
In this context, blood eosinophilia might represent a clinically actionable trait to guide diagnosis and personalized therapy in chronic airway diseases even if it should not be targeted in isolation but be integrated into a multidimensional assessment.
TL;DR
In this context, blood eosinophilia might represent a clinically actionable trait to guide diagnosis and personalized therapy in chronic airway diseases even if it should not be targeted in isolation but be integrated into a multidimensional assessment.
Key findings
- While eosinophilic inflammation is a common feature of asthma, COPD is usually characterized by neutrophilic inflammation, even if, a subset of patients with COPD has eosinophilic inflammation.
- In this context, blood eosinophilia might represent a clinically actionable trait to guide diagnosis and personalized therapy in chronic airway diseases even if it should not be targeted in isolation but be integrated into a multidimensional assessment.
What they did
Considering the new diagnosis, he was prescribed mepolizumab on top of triple inhaled therapy. After 1 year, the clinical response was excellent in terms of symptoms control, exacerbations reduction and OCS sparing, despite no improvement in lung function. Starting from this clinical case, the aim of this mini review is to describe the role of eosinophilic inflammation in asthma and COPD.
Full abstract (original)
Background: Nowadays, the management of chronic obstructive airway diseases is shifting from traditional diagnostic labels toward a precision medicine approach based on "treatable traits." Among these, blood eosinophilia is emerging as a biomarker of type 2 (T2) inflammation across asthma and chronic obstructive airway diseases (COPD), even if its role as diagnostic tool and therapeutic target remains debated. In this manuscript we presented a clinical case of a 60-year-old male, former mild smoker (5 p/y), initially diagnosed with severe COPD with persistent airflow limitation, frequent severe exacerbations and persistent eosinophilia, but a history of asthma and nasal polyposis. After six months with optimization of inhaled therapy and clinical reassessment, the diagnosis of "severe COPD" shifted to the diagnosis of "severe eosinophilic asthma".
What they did: Considering the new diagnosis, he was prescribed mepolizumab on top of triple inhaled therapy. After 1 year, the clinical response was excellent in terms of symptoms control, exacerbations reduction and OCS sparing, despite no improvement in lung function. Starting from this clinical case, the aim of this mini review is to describe the role of eosinophilic inflammation in asthma and COPD.
Results & conclusions: While eosinophilic inflammation is a common feature of asthma, COPD is usually characterized by neutrophilic inflammation, even if, a subset of patients with COPD has eosinophilic inflammation. In this context, blood eosinophilia might represent a clinically actionable trait to guide diagnosis and personalized therapy in chronic airway diseases even if it should not be targeted in isolation but be integrated into a multidimensional assessment.
Abstract © the authors / Frontiers in Immunology (2026). Reproduced here for discussion and indexing, with attribution. Read the original at https://doi.org/10.3389/fimmu.2026.1868910 · PubMed 42305539.
Why it matters for pharma & biotech
- Relevant to Immunology teams tracking Frontiers in Immunology for new targets, mechanisms and biomarkers.
- Because it reports human data, it can inform indication, endpoint and comparator decisions faster than preclinical work.
- For searchers: the full abstract is reproduced below, so you can judge relevance before opening the publisher page.
Limitations & what to check in the full text
- This brief is based on the published abstract only. Effect sizes, subgroup results and safety detail in the full text may qualify the headline findings.
- As a review, this paper synthesises prior studies rather than reporting new experimental data; weight it accordingly.
- The abstract reports its conclusions qualitatively, without headline effect sizes — read the full text before citing a magnitude.
Frequently asked questions
What did this Frontiers in Immunology study find?
In this context, blood eosinophilia might represent a clinically actionable trait to guide diagnosis and personalized therapy in chronic airway diseases even if it should not be targeted in isolation but be integrated into a multidimensional assessment.
What type of study is this?
It is a review / perspective, published in Frontiers in Immunology in 2026. Considering the new diagnosis, he was prescribed mepolizumab on top of triple inhaled therapy.
Where can I read the original paper?
The original is at the publisher via DOI 10.3389/fimmu.2026.1868910. PubMed ID: 42305539. BioStudioAI reproduces the abstract for discussion and links to the source.
This brief: BioStudioAI Journal Watch, 29 October 2026. https://biostudioai.com/blog/papers/is-blood-eosinophilia-a-treatable-trait-in-chronic-obstructive-airway-di-868910/
Reading papers is step one. Analysing the data is the work.
BioStudioAI turns raw lab files into QC'd results, statistics, figures, reports and slides — hosted on your servers, every number computed, nothing typed.
Open BioStudioAI More guides